PI3Kα
45 programs · 42 companies
Programs
45
Companies
42
Active Trials
23
Targeting PI3Kα
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | SchizophreniaObesity | |
| Rimamavacamten | Merck & Co | Phase 1 | Ewing Sarcoma | |
| Fixazanubrutinib | Amgen | Phase 2 | TTR Amyloidosis | |
| GMA-1468 | Genmab | NDA/BLA | T2DNMOSD | |
| 369-789 | Hansoh Pharma | Phase 3 | FTDMS | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | ACCSCLC | |
| Sematenlimab | Samsung Biologics | Phase 3 | DLBCLT2D | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | HNSCCHCC | |
| Terarasimod | Krystal Biotech | Phase 1/2 | Cervical Ca | |
| Tirasacituzumab | Disc Medicine | NDA/BLA | PAHRA | |
| CSL-5084 | CSL Limited | NDA/BLA | Urothelial Ca | |
| IPN-4133 | Ipsen | NDA/BLA | NASHWilms | |
| 600-2830 | Jiangsu Hengrui | Preclinical | Atopic DermPsA | |
| Zenozumab | Opthea | Phase 3 | HCCNASH | |
| UCL-IIT-799 | UCLA Health | Preclinical | PBC | |
| UCL-IIT-899 | UCLA Health | Preclinical | PsA | |
| IMM-7144 | ImmunoGen (AbbVie) | Approved | Bladder CaEoE | |
| Zenotuximab | Tome Bio | Phase 1/2 | Prostate CaALL | |
| Geliglumide | Metsera | Phase 1 | BCCCF | |
| PCL-8414 | PharmaCielo | Phase 2/3 | Urothelial CaRCC | |
| ELO-2344 | Eloxx Pharma | Phase 3 | Prostate Ca | |
| MRN-8142 | Marinus Pharma | Phase 2/3 | DravetNASH | |
| Gozelemzoparlimab | Volato Group | Approved | HCC | |
| Sovainavolisib | Kelun-Biotech | NDA/BLA | UCFSGS | |
| GC-7403 | GC Cell | Phase 2/3 | ObesityGA | |
| TOT-3942 | Totus Med | Preclinical | GA | |
| CAP-150 | Capsida Bio | NDA/BLA | MGALL | |
| Talarasimod | Homology Med | Phase 3 | ALLDLBCL | |
| Rilulucimab | Homology Med | NDA/BLA | Huntington'sCF | |
| TRV-1449 | Targovax | Phase 2 | GBMAlzheimer's | |
| Fixacagene | Meiji Pharma | Preclinical | NSCLC | |
| Gelizumab | Shanghai Fosun | Phase 1/2 | FSGSNarcolepsy | |
| Terafotisoran | Adaptimmune | Phase 1/2 | ALSSchizophrenia | |
| ITA-9145 | Itamar Medical (Zoll) | NDA/BLA | Angelman | |
| Liralemzoparlimab | NTC Pharma | Phase 3 | AngelmanCKD | |
| Pemimavacamten | Pierre Fabre | Phase 1 | WMLGS | |
| Mirimavacamten | Hanmi Pharm | Phase 1/2 | Bladder Ca | |
| HYP-6990 | Hypera Pharma | Preclinical | RettPompe | |
| Zenoinavolisib | Insud Pharma | Preclinical | PsA | |
| TAT-IIT-832 | Tata Memorial Hosp | NDA/BLA | Alzheimer's | |
| Pexatinib | Zhifei Biological | Phase 3 | AS | |
| Elratuximab | GH Research | NDA/BLA | MSIgAN | |
| Voxatenlimab | Waters Corp | Approved | GANASH | |
| Darasertib | Helsinn | Phase 1/2 | SCDAtopic Derm | |
| Voxazasiran | MedPacto | Phase 1 | PAHET |